(Q38125603)

29 August 2017

title

Breaking a vicious cycle (English)

1 reference

29 August 2017

9

David Ransohoff

1 reference

29 August 2017

3

Carolyn Compton

1 reference

29 August 2017

Daniel F Hayes

1

1 reference

29 August 2017

Jeff Allen

2

1 reference

29 August 2017

Gary Gustavsen

4

1 reference

29 August 2017

Debra G B Leonard

5

1 reference

29 August 2017

Robert McCormack

6

1 reference

29 August 2017

Lee Newcomer

7

1 reference

29 August 2017

Kristin Pothier

8

1 reference

29 August 2017

Richard L Schilsky

10

1 reference

29 August 2017

Ellen Sigal

11

1 reference

29 August 2017

Sheila E Taube

12

1 reference

29 August 2017

Sean R Tunis

13

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 July 2013

1 reference

Science Translational Medicine

29 August 2017

published in

1 reference

29 August 2017

volume

5

1 reference

29 August 2017

issue

196

1 reference

29 August 2017

page(s)

196cm6

1 reference

AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Genomics and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Use of archived specimens in evaluation of prognostic and predictive biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Excess in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Clinical trial designs for predictive marker validation in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Randomized clinical trials with biomarkers: design issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Development of the 21-gene assay and its application in clinical practice and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Is there a role for circulating tumor cells in the management of breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Targeting adjuvant chemotherapy: a good idea that needs to be proven!

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Publication of tumor marker research results: the necessity for complete and transparent reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Biospecimen reporting for improved study quality (BRISQ)

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Biomarker studies: a call for a comprehensive biomarker study registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

The pharmaceutical industry--to whom is it accountable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

Biospecimen reporting for improved study quality (BRISQ)

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3005950

10.1126/SCITRANSLMED.3005950

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference